TRACER [F-18] RDG-K5 Carotid Plaque Imaging Study (K5-C200)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03364270|
Recruitment Status : Recruiting
First Posted : December 6, 2017
Last Update Posted : February 12, 2019
|First Submitted Date ICMJE||December 1, 2017|
|First Posted Date ICMJE||December 6, 2017|
|Last Update Posted Date||February 12, 2019|
|Actual Study Start Date ICMJE||October 10, 2018|
|Estimated Primary Completion Date||December 31, 2019 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Assessment of the uptake of [F-18] RGD-K5 by carotid plaque with PET/MRI imaging [ Time Frame: within 96 hrs of a stroke or TIA (transient ischemic attack) ]
To assess the uptake of [F-18] RGD-K5 by carotid plaque with PET/MRI imaging in participants prior to carotid endarterectomy and thereby determine if carotid plaque that causes significant stenosis [in participants being considered for carotid endarterectomy (CEA)] is characterized by increased integrin expression and enhanced angiogenesis.
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT03364270 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
||Collection safety data of [F-18] RGD-K5 in participants with carotid atherosclerosis. [ Time Frame: at the time of imaging and immediately following imaging ]
to collect safety data of [F-18] RGD-K5 when given with PET/MRI imaging
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title ICMJE||TRACER [F-18] RDG-K5 Carotid Plaque Imaging Study|
|Official Title ICMJE||An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis|
The purpose of this study is to investigate the ability of a new investigational agent compound [F-18] labeled RGD-K5 to detect unstable atherosclerotic plaque in the carotid artery of subjects being considered for carotid endarterectomy (CEA), and to confirm this ability through tissue analysis of samples of carotid artery plaques that will be collected during the planned carotid surgery. [F-18] RGD-K5 is a radioactive tracer used in imaging to detect active growth of new blood vessels and presence of macrophages. Patients with unstable plaque may be prone to rupture of the plaque due to increase in macrophage activity and growth of new blood vessels. [F-18] RGD-K5 is an investigational agent, which means that it has not yet been approved by the US Food and Drug Administration (FDA).
Unstable atherosclerotic plaque that is prone to rupture is characterized by an increase in the number of macrophages and enhanced angiogenesis. Both neovascular endothelium and macrophages exhibit increased Alpha-v beta3 integrin expression. PET (Positron Emission Tomography) imaging of [F-18] RGD-K5 uptake may identify carotid plaque with increased inflammation and neovascularization and may therefore detect unstable plaque in participants with carotid artery stenosis.
Prior to Dr. Tamarappoo's relocation to Cedars Sinai Medical Center (CSMC), 5 subjects were enrolled at the Cleveland Clinic where PET-CT (Positron Emission Tomography - Computed Tomography) was performed. 6 subjects will be scanned at Cedars using PET-MRI (Positron emission tomography-magnetic resonance imaging). Based on preliminary data with PET-CTA, the investigator strongly believes the study will be able to reproducibly detect significant [F-18] RGD-K5 uptake in plaque from symptomatic patients. Ultimately, demonstrating preferential [F-18] RGD-K5 uptake in symptomatic patients will significantly impact the way in which patients with carotid plaque (at risk for stroke) are treated and it may prevent unnecessary surgical and endovascular procedures in this population
The primary objectives of this exploratory study are:
Potential subjects will be identified and approached during an inpatient or outpatient clinical visit by a member of the research team. Potential subjects will be identified by their treating physicians and referred to the researchers. Patients' private and identifiable information will not be shared prior to receiving permission from the patient to do so
Summary of research procedures:
Physical exam and vital Signs:
Height, weight, temperature, heart rate and blood pressure will be checked before beginning the imaging tests. Subjects' heart rate and blood pressure will be checked again after each of the two PET/MRI images, and as needed.
Patients will also be asked about the presence of ICD, pacemaker or any metallic implants that would not be compatible with the MRI magnet (presence of MRI non-compatible devices will be an exclusion criteria)
If labs have been done and the lab values meet the criteria to participate in this study, the investigators will not need to collect these labs again on the day of testing. If these labs have not been collected within 30 days prior to the research imaging tests, the investigators will draw a tube of blood to check kidney function and other necessary blood values prior to the research testing. Patients with a glomerular filtration rate (GFR) <40ml/min will be excluded from the study.
Urine Pregnancy test:
This will only need to be done in female subjects of childbearing potential. This will need to be checked prior to scheduling subjects' research imaging tests. If subjects' tests are schedules more than 2 days (48 hours) since first checked, this test will need to be rechecked on the day of subjects' research imaging testing.
An ECG (electrocardiogram) will be done to assess subjects' heart rhythm before the testing begins, and after each of the PET scans.
A catheter will be inserted into subjects' arm. It is through this IV catheter that the dose of [F-18] RGD-K5 will be given prior to imaging.
Research PET/MRI Imaging of the Carotid Arteries:
2 hours after receiving the dose of [F-18] RGD-K5 PET/MRI imaging of subjects' neck (carotid arteries) will be performed. Subjects will be lying on subjects' back with a head fixation device supporting subjects' head to prevent Subjects from moving subjects' head while the images are taken. This scan will take about 30-45 minutes. Subjects will be permitted to get up and move around between receiving the radiotracer and imaging. Subjects will be asked to drink a glass of water before receiving the dose of [F-18] RGD-K5.
Histology and Immunohistochemistry:
During Subjects carotid endarterectomy(CEA) which is a clinically indicated procedure, atherosclerotic plaque will be removed. A sample of this plaque will be collected and taken to the histology laboratory at Cedars Sinai for analysis.
Follow Up phone call:
Subjects will be contacted by phone the day after subjects' PET scans to ask if Subjects have had any medical problems and what medications Subjects have taken since the PET scan. If Subjects were seen by a doctor to be evaluated for a medical problem, the investigators may ask permission to contact the doctor or hospital to obtain copies of subjects' medical records
Research poses greater than minimal risk
There is no personal benefit to participants by participating in this research study.
The knowledge to be gained from this research may be beneficial for other patients, society or science.
The detection by the imaging protocol of unstable atherosclerotic plaque in the carotid artery will not result in any change in their standard of care.
The potential benefit of the study to the patient is that it will allow the physician treating the patient to know the entire extent of the carotid plaque, plaque composition and will inform them of the anatomy of the carotid artery in question.
Furthermore, it will provide information about plaque in the contralateral carotid artery and if that plaque has a high degree of inflammation. If a high inflammatory burden is noted in the contralateral carotid artery, there will be more vigilance in monitoring these patients.
Summary of process by which confidentiality will be maintained:
Research records will be stored in a locked cabinet in a secure location Electronic research records will be stored in a shared network folder on the CSMC network. The list linking the assigned code number to the individual subject will be maintained separately from the other research data. Only certified research personnel who are listed on the approved Institutional Review Board (IRB) application will be given access to identifiable subject information. Research related data and patient/subject information will never be stored on a researcher's personal (private) computer or laptop. Study data will be coded upon abstraction so that Direct Identifiers** are maintained separately from the data set.
Summary of data and safety monitoring plan:
The study will be monitored only by the study investigators and/or sponsor.
How does participation in the research differ from the receipt of standard care:
RISKS OF THE STUDY
As with any research study, there may be adverse events or side effects that are currently unknown and it is possible that certain of these unknown risks could be permanent, serious or life threatening. The study doctor will inform subjects of any significant new information that is discovered during this trial.
Risks of the Study Drug Based upon the toxicity profile to be administered as a single dose, the purity and impurity profile of [F-18] RGD-K5, no risk of adverse events is anticipated for this study.
MRI is not associated with any radiation risk.
MRI non-compatible devices such as pacemakers, ICD (implantable cardioverter defibrillator) and metallic implants may cause artifacts in imaging and device malfunction as well as local tissue injury.
Contrast used for MRI is associated with minimal risk among patients who are free of significant renal dysfunction.
When injected into the body, gadolinium contrast medium makes certain tissues, abnormalities or disease processes more clearly visible on a magnetic resonance imaging scan. They are used to improve the clarity of the scanned images or pictures of the body's internal structures.
Gadolinium contrast medium is given by intravenous injection.
The risk of gadolinium contrast is minimal in patients without severe renal disease.
The most common adverse effects of gadolinium agents are
More serious allergic reactions that are life threatening are rare. Gadolinium is not safe for people with late stage kidney disease or who have had a liver transplant. Gadolinium-based contrast agents increase the risk for a rare, but serious adverse reaction, called nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Patients with kidney disease are at increased risk of developing NSF. NSF may cause skin thickening, joint pain and/or swelling, causing feelings of burning, itching and pain that can be severe. In very rare cases, NSF can lead to lung and heart problems and may be life threatening. Participants will have a blood test to measure kidney function and if the blood test is abnormal, they will not be permitted to receive gadolinium.
There is a very small risk of mild headache and local pain. Rarely (<1% of the time) it can cause low blood pressure and lightheadedness. This can be treated immediately with IV fluids. More serious allergic reactions that are life threatening are rare. Gadolinium is not safe for people with late stage kidney disease or who have had a liver transplant.
As with all research procedures and administration of study drugs, subjects will be monitored at all times.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Phase 2|
|Study Design ICMJE||Intervention Model: Single Group Assignment
Intervention Model Description:
Pilot studyMasking: None (Open Label)
Primary Purpose: Diagnostic
|Condition ICMJE||Carotid Arteries|
|Intervention ICMJE||Drug: PET/CT Imaging with [F-18] RGD-K5
PET Imaging/scan with [F-18] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
|Study Arms ICMJE||Experimental: [F-18] RDG-K5
PET/CT Imaging with administration of [F-18] RGD-K5
Intervention: Drug: PET/CT Imaging with [F-18] RGD-K5
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Recruiting|
|Estimated Enrollment ICMJE
|Original Estimated Enrollment ICMJE||Same as current|
|Estimated Study Completion Date ICMJE||June 30, 2020|
|Estimated Primary Completion Date||December 31, 2019 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
1. Patients presenting
a. to the neurologist for evaluation of stroke or TIA (Symptomatic) with: i. Symptomatic patients with plaque ≥70% in at least one carotid artery that would be implicated as the source of embolus responsible for the stroke/TIA. b. or to the vascular surgeon for CEA (Asymptomatic) with: i. asymptomatic patients with a luminal stenosis of ≥70% in at least one carotid artery (stable plaque) referred for CEA ii. age-matched by deciles to symptomatic patients
|Ages ICMJE||18 Years and older (Adult, Older Adult)|
|Accepts Healthy Volunteers ICMJE||No|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT03364270|
|Other Study ID Numbers ICMJE||Pro00047624|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||
|IPD Sharing Statement ICMJE||Not Provided|
|Responsible Party||Balaji Tamarappoo, Cedars-Sinai Medical Center|
|Study Sponsor ICMJE||Balaji Tamarappoo|
|Collaborators ICMJE||Not Provided|
|PRS Account||Cedars-Sinai Medical Center|
|Verification Date||February 2019|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP